Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2023)

Silence Therapeutics has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $73.2 million for Q4 2023.

• Total Non-Current Liabilities for Q4 2023 came in at $73.2 million, down 1.65% year-over-year; the trailing twelve-month figure through Dec 2023 was $73.2 million (down 1.65% YoY), and the FY2023 annual result was $73.2 million, down 6.79% from the prior year.
• Total Non-Current Liabilities came in at $73.2 million for Q4 2023 at Silence Therapeutics, down from $74.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $97.7 million in Q4 2021 to a low of $19.9 million in Q4 2019.
• The 5-year median for Total Non-Current Liabilities is $73.2 million (2023), against an average of $66.6 million.
• Across the five-year window, Total Non-Current Liabilities jumped 239.82% in 2020 and retreated 23.81% in 2022, its largest moves.
• Silence Therapeutics' Total Non-Current Liabilities stood at $19.9 million in 2019, then surged by 239.82% to $67.8 million in 2020, then jumped by 44.17% to $97.7 million in 2021, then slipped by 23.81% to $74.5 million in 2022, then slipped by 1.65% to $73.2 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $73.2 million (Q4 2023), $74.5 million (Q4 2022), and $97.7 million (Q4 2021), per Business Quant data.